DBV Technologies S.A. (NASDAQ:DBVT – Get Rating) – Analysts at HC Wainwright reduced their Q2 2023 earnings per share (EPS) estimates for DBV Technologies in a research report issued to clients and investors on Tuesday, May 9th. HC Wainwright analyst A. Fein now forecasts that the company will post earnings of ($0.13) per share for the quarter, down from their previous forecast of ($0.12). HC Wainwright has a “Buy” rating and a $10.00 price objective on the stock. The consensus estimate for DBV Technologies’ current full-year earnings is ($0.97) per share. HC Wainwright also issued estimates for DBV Technologies’ Q3 2023 earnings at ($0.13) EPS, Q4 2023 earnings at ($0.14) EPS, Q4 2023 earnings at ($0.14) EPS, FY2023 earnings at ($0.51) EPS, FY2024 earnings at ($0.47) EPS and FY2025 earnings at ($0.07) EPS.
DBV Technologies (NASDAQ:DBVT – Get Rating) last issued its earnings results on Thursday, March 2nd. The company reported ($0.23) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.23). DBV Technologies had a negative return on equity of 48.25% and a negative net margin of 778.60%. The company had revenue of ($1.30) million during the quarter, compared to analysts’ expectations of $2.10 million.
DBV Technologies Trading Up 12.1 %
NASDAQ:DBVT opened at $1.85 on Thursday. The firm has a market cap of $348.31 million, a P/E ratio of -3.03 and a beta of 1.27. The stock’s 50 day simple moving average is $1.62 and its 200-day simple moving average is $1.49. DBV Technologies has a 12-month low of $1.08 and a 12-month high of $3.43.
Institutional Investors Weigh In On DBV Technologies
A number of large investors have recently modified their holdings of DBVT. Braidwell LP acquired a new position in shares of DBV Technologies in the 4th quarter valued at about $18,525,000. VR Adviser LLC bought a new position in DBV Technologies during the fourth quarter valued at $29,258,000. Fairmount Funds Management LLC lifted its position in shares of DBV Technologies by 46.2% during the third quarter. Fairmount Funds Management LLC now owns 7,064,964 shares of the company’s stock worth $12,505,000 after acquiring an additional 2,233,809 shares in the last quarter. RA Capital Management L.P. purchased a new stake in shares of DBV Technologies in the third quarter worth $6,593,000. Finally, Vivo Capital LLC purchased a new stake in DBV Technologies during the third quarter valued at about $4,795,000. Institutional investors and hedge funds own 18.37% of the company’s stock.
DBV Technologies Company Profile
DBV Technologies SA is a clinical-stage biopharmaceutical company, which engages in the research and development of epicutaneous immunotherapy products. The firm focuses on the development of Viaskin, an electrostatic patch, which may offer a convenient, self-administered, and non-invasive immunotherapy to patients.
- Get a free copy of the StockNews.com research report on DBV Technologies (DBVT)
- Thinking Of Buying The Dip On JD.com? Consider This First
- Wynn Resorts: A Winning Bet for 2023
- A Royally Good Time To Buy The Walt Disney Company
- 3 Surprising Stocks Leading Growth Over Value
- Copa Holdings Is Looking For A Comeback, Its Dividend Agrees
Receive News & Ratings for DBV Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DBV Technologies and related companies with MarketBeat.com's FREE daily email newsletter.